Ultratrutide: What It Is, What the Research Shows, and What Remains Unknown

Ultratrutide is a new name in the metabolic-signaling space. Here's a research-focused look at how the product is being described, what public filings and published research can actually tell us, and where the evidence is still limited.

What Is Ultratrutide?

InstaMed's current product materials describe Ultratrutide as a “multi-signal metabolic peptide” working through pathways connected to GLP-1, GIP, glucagon, and a ghrelin-receptor component. The product is also marketed as “ULTRATRUTIDE (GLP-4).” Those descriptions come from the product's commercial materials; they are not the same thing as a published clinical-trial designation or an FDA-established drug class.

The commercial concept is therefore broader than a conventional GLP-1-only product: several metabolic signaling pathways are presented as part of one peptide platform. The scientific question is whether that proposed mechanism translates into measurable pharmacology, safety, and clinical outcomes in humans.

Is “GLP-4” a New GLP Hormone?

Not based on the evidence I could identify. In the materials reviewed for this article, “GLP-4” is used as the product's marketing descriptor for its proposed four-pathway signaling concept. The established literature uses names such as GLP-1 receptor agonist, GIP receptor agonist, glucagon receptor agonist, and other specific receptor targets.

That distinction matters for research readers. A label such as “GLP-4” should not be interpreted as proof of a newly established fourth GLP hormone or a new FDA drug category.

What Does the Published Research Actually Show?

This is the most important part of the review: I did not find a published human clinical trial specifically evaluating Ultratrutide under that name in the searches I ran for PubMed and ClinicalTrials.gov. That means we should not borrow clinical results from other peptides and present them as Ultratrutide results.

There is, however, substantial published research on related multi-receptor biology. For example, retatrutide has been studied in randomized human trials as a GIP, GLP-1, and glucagon receptor agonist. A 2023 phase 2 trial published in the New England Journal of Medicine evaluated 338 adults with obesity or overweight and reported dose-dependent weight reduction over 48 weeks. Those results apply to retatrutide, not Ultratrutide. citeturn4search0

ClinicalTrials.gov also lists ongoing retatrutide studies sponsored by Eli Lilly. Again, those are studies of retatrutide (LY3437943), not evidence for Ultratrutide. citeturn0search7

What About Oral or Buccal Peptide Delivery?

The delivery technology is a separate scientific question from the identity and clinical evidence for Ultratrutide itself. InstaMed describes its InstaRelease platform as an oral dissolving strip designed for trans-oral mucosal delivery. The company has publicly described pharmacokinetic work involving glutathione and has said its platform is supported by patent activity. citeturn6view1turn3search2

In other words, evidence that a delivery platform can move a particular active ingredient through the oral mucosa does not automatically establish the pharmacokinetics, safety, or clinical effectiveness of every peptide placed into that platform. Each active ingredient and formulation needs its own evidence.

What Public Filings Can We Verify?

There is a public U.S. trademark application for ULTRATRUTIDE, filed April 20, 2026 by Lionheart Enterprises, LLC. The filing describes goods including nutraceuticals, peptide-based dietary supplements, oral dissolving strips, and oral dissolving films. A trademark filing establishes a claimed commercial mark and listed goods; it does not establish clinical efficacy or FDA approval. citeturn6view2

Separately, InstaMed has publicly stated that it had nine pending patents related to its peptide delivery platform as of December 2025. That is a company statement about its intellectual-property portfolio, not evidence that Ultratrutide itself has an issued patent or that a patent claim proves clinical performance. citeturn6view1

Why Retatrutide Research Keeps Coming Up

Researchers and consumers naturally compare new metabolic peptides with retatrutide because retatrutide is one of the best-studied next-generation multi-receptor candidates. The published phase 2 obesity trial described retatrutide as a triple agonist of GIP, GLP-1, and glucagon receptors. citeturn4search0

That research is useful background for understanding why multi-receptor metabolic signaling is an active research area. But it should remain background. Retatrutide data cannot be used as proof of Ultratrutide's effects.

What We Know vs. What We Don't Know

• We can verify: Ultratrutide is currently being marketed as an InstaMed metabolic-signaling peptide and oral dissolving strip product. citeturn6view0
• We can verify: the product's commercial description references GLP-1, GIP, glucagon, and a ghrelin-receptor component. citeturn6view0
• We can verify: a ULTRATRUTIDE trademark application was filed in the United States in April 2026. citeturn6view2
• We can verify: InstaMed has publicly reported research and intellectual-property activity around its InstaRelease delivery platform. citeturn6view1
• Not established by the sources reviewed: published human clinical efficacy data specifically for Ultratrutide.
• Not established by the sources reviewed: that results from retatrutide, semaglutide, or tirzepatide should be attributed to Ultratrutide.
• Not established by the sources reviewed: FDA approval of Ultratrutide as a drug.